期刊
MOLECULAR CANCER THERAPEUTICS
卷 10, 期 4, 页码 569-579出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-10-0615
关键词
-
类别
资金
- Plan Nacional de Investigacion Cientifica, Desarrollo e Innovacion Tecnologica (I+D+I), iniciativa Ingenio
- programa Consolider and Instituto de Salud Carlos III (ISCIII)/FEDER [RD06/0020/0109]
- ISCIII/FEDER - Subdireccion General de Evaluacion y Fomento de la Investigacion [PS09/01594]
- DIUE de la Generalitat de Catalunya
Recently, the anaplastic lymphoma kinase (ALK) has been found to be altered in several solid and hematologic tumors. Novel drugs targeting this tyrosine kinase receptor are under development, and early clinical trials are showing promising activity in non-small cell lung cancer patients with ALK+ tumors. Here, we review the structure and function of the ALK receptor, the mechanisms associated with its deregulation in cancer, methods for ALK detection in tumor samples, its potential as a new marker for candidate patient selection for tailored therapy, and novel drugs under development that target ALK. Mol Cancer Ther; 10(4); 569-79. (C) 2011 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据